Host-Virus Interface in Persistent SARS-CoV-2 Infections: Viral Characteristic Evolution and Gene Expression Profiling Analysis.

Publication date: Jun 27, 2025

Persistent SARS-CoV-2 infections involve prolonged viral replication and immune system interactions, potentially driving viral evolution and immune escape. This study examines viral characteristics and host gene expression changes in persistent infections. The nasopharyngeal samples from four patients with persistent SARS-CoV-2 infections at Tottori University Hospital, Japan, were analyzed. Viral isolates were cultured, and infectivity was assessed using TCID assays. To investigate host responses, RNA sequencing (RNA-seq) was performed to identify differentially expressed genes (DEGs), and Gene Ontology (GO) enrichment analysis mapped affected biological pathways. Viral genome sequencing detected mutations associated with prolonged infection. The results showed significant infectivity differences between early- and late-phase infection. Gene expression analysis revealed a strong early phase of pro-inflammatory response (IL6, TNF, IL1B, CXCL10) followed by immune suppression. GO enrichment analysis highlighted inflammation and cytokine-mediated immune pathways. Genomic sequencing identified mutations in ORF1ab and the spike (S) protein, potentially aiding immune escape. The findings underscore that SARS-CoV-2 adapts during persistent infections, altering infectivity and immune responses. These highlight the need for continued monitoring of prolonged infections to mitigate immune escape and viral evolution.

Open Access PDF

Concepts Keywords
Cultured COVID-19
Genome Evolution, Molecular
Hospital gene expression
Japan Gene Expression Profiling
Late Genome, Viral
GO enrichment
Host-Pathogen Interactions
host–virus interaction
Humans
immune response
Male
Middle Aged
Mutation
persistent infection
SARS-CoV-2
SARS-CoV-2
Spike Glycoprotein, Coronavirus
Spike Glycoprotein, Coronavirus
viral evolution

Semantics

Type Source Name
disease IDO host
disease MESH SARS-CoV-2 Infections
pathway KEGG Viral replication
pathway REACTOME Immune System
disease MESH persistent infections
disease IDO infectivity
disease MESH infection
disease MESH inflammation
disease IDO protein
disease MESH Infectious Diseases
drug DRUGBANK Coenzyme M
disease IDO immune response
disease MESH respiratory failure
disease MESH death
disease MESH viral shedding
disease MESH cancer
disease MESH rheumatoid arthritis
pathway KEGG Rheumatoid arthritis
disease MESH hypertension
disease MESH Esophageal cancer
disease MESH pneumonia
disease MESH sore throat
drug DRUGBANK Prednisolone
disease MESH Lung cancer
drug DRUGBANK Dexamethasone
disease IDO assay
disease IDO biological process
disease IDO pathogen
disease MESH PRRs
drug DRUGBANK Tretinoin
disease IDO acute infection
disease IDO role
disease IDO process
disease IDO replication
disease MESH cytokine storms
disease MESH viral infections
pathway REACTOME Translation
disease MESH viral load
drug DRUGBANK Methionine
drug DRUGBANK Phosphate ion
drug DRUGBANK L-Glutamine
disease IDO reagent
drug DRUGBANK Pentaerythritol tetranitrate
drug DRUGBANK Water
drug DRUGBANK Amlodipine
drug DRUGBANK Tromethamine
drug DRUGBANK Edetic Acid
disease IDO quality
drug DRUGBANK Nonoxynol-9

Original Article

(Visited 3 times, 1 visits today)